# Triple Negative Breast Neoplasms trials: 236 new

Updated November 3, 2026.

236 clinical studies in Triple Negative Breast Neoplasms were first posted on ClinicalTrials.gov from November 12, 2024 to November 3, 2026; 73 have an industry sponsor and 207 are recruiting or about to. The newest, NCT07914309, was posted on November 3, 2026: Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer (Washington University School of Medicine).

## The full list

New Triple Negative Breast Neoplasms clinical trials: 236 rows for $11.80, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 10 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/triple-negative-breast-neoplasms

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 236
- Industry sponsored: 73
- Recruiting or not yet: 207
- Latest posted: November 3, 2026

## Newest trials

The newest 100 of 236, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 3, 2026 | NCT07914309 | Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer | Washington University School of Medicine | Phase 2 | Not yet recruiting | Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC), Breast Cancer | 17 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914309) |
| October 27, 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | Medsyn Biopharma, LLC | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer... | 75 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899632) |
| October 26, 2026 | NCT07894874 | A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors. | InventisBio Yiqi Beijing Limited | Phase 1 | Not yet recruiting | Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer | 204 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894874) |
| October 21, 2026 | NCT07884721 | Fasten Onco Digital Therapy During Neoadjuvant Treatment for Triple-Negative Breast Cancer | FASTEN | Not applicable | Not yet recruiting | Triple-Negative Breast Cancer (TNBC) | 144 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884721) |
| October 20, 2026 | NCT07884201 | Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment | Fudan University | Phase 2 | Not yet recruiting | Breast Cancer, TNBC - Triple-Negative Breast Cancer, Immunotherapy | 572 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884201) |
| October 19, 2026 | NCT07880600 | Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer | Fujian Cancer Hospital | Observational | Recruiting | Breast Neoplasm Female, Triple -Negative Breast Cancer | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07880600) |
| October 19, 2026 | NCT07879911 | A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or... | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Triple Negative Breast Cancer | 550 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07879911) |
| October 15, 2026 | NCT07876557 | A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative... | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 | Recruiting | Triple-negative Breast Cancer | 184 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876557) |
| October 9, 2026 | NCT07867470 | TROPION Breast Respond in 1L TNBC | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Observational | Not yet recruiting | Unresectable Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer | 400 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867470) |
| October 7, 2026 | NCT07862751 | US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving... | Emory University | Phase 2 | Not yet recruiting | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma | 32 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862751) |
| October 5, 2026 | NCT07857486 | Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer | Institut Paoli-Calmettes | Phase 2 | Not yet recruiting | Early Triple-Negative Breast Cancer | 84 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857486) |
| October 2, 2026 | NCT07856225 | Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer | Fundación Santa Fe de Bogota | Observational | Recruiting | Breast Neoplasms, Triple Negative Breast Neoplasms, HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer | 370 | Colombia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856225) |
| September 29, 2026 | NCT07847398 | Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer. | Centre Antoine Lacassagne | Not applicable | Not yet recruiting | Triple-negative Breast Cancer (TNBC), Stage II-III | 50 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07847398) |
| September 28, 2026 | NCT07844473 | Use of Magtrace Bracketing for Excision of Lesion and Sentinel Lymph Node Localization in Breast Conserving Surgery for Breast Cancer | King Faisal Specialist Hospital & Research Center | Not applicable | Recruiting | Breast Cancer With Low to Intermediate HER2 Expression, Breast Cancer (Triple Negative Breast Cancer (TNBC)), Breast... | 35 | Saudi Arabia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844473) |
| September 22, 2026 | NCT07833891 | Senocohort: Identification of Predictive Biomarkers in Breast Cancer Treatment | Assistance Publique - Hôpitaux de Paris | Observational | Not yet recruiting | Breast Cancer, Breast Cancer (Triple Negative Type) | 500 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833891) |
| September 18, 2026 | NCT07828652 | Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer... | Yeon Hee Park | Observational | Not yet recruiting | TNBC - Triple-Negative Breast Cancer | 2,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828652) |
| September 18, 2026 | NCT07827079 | A Study of Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBC | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 | Completed | Breast Cancer (Triple Negative Breast Cancer (TNBC)), Chemeotherapy | 36 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827079) |
| September 15, 2026 | NCT07820228 | Survival Analysis of Early Triple Negative Breast Cancer (TNBC) Women Treated With Dose Dense Sequential Adjuvant Chemotherapy | Hellenic Cooperative Oncology Group | Observational | Completed | Triple Negative Breast Cancer | 3,648 | Greece | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07820228) |
| September 8, 2026 | NCT07808086 | Role of Tumor Microbiota in the Response to Neoadjuvant Therapy in Patients Affected by Triple Negative Breast Cancer | Istituti Clinici Scientifici Maugeri SpA | Observational | Recruiting | Breast Cancer | 30 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808086) |
| September 3, 2026 | NCT07801508 | A Study of \[68Ga\]Ga-DWJ155 in Adult Patients With Solid Tumors | Novartis Pharmaceuticals | Phase 1 | Recruiting | Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer, Triple-negative Breast Cancer, Advanced Non-small... | 66 | Australia, Japan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801508) |
| August 26, 2026 | NCT07788222 | Sacituzumab Govitecan and Q901 in Advanced TNBC | Yonsei University | Phase 2 | Not yet recruiting | Triple Negative Breast Neoplasms | 48 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07788222) |
| August 26, 2026 | NCT07786428 | Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC | University of Texas Southwestern Medical Center | Phase 2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC) | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07786428) |
| August 20, 2026 | NCT07776951 | Physical Activity and Healthy Aging: Promoting Cardio-metabolic Capacity to Fight Chronic Inflammation and Improve Outcomes in Breast... | University of Milan | Not applicable | Recruiting | Breast Cancer | 126 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776951) |
| August 17, 2026 | NCT07768436 | A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Adenocarcinoma of the Breast, Breast Cancer, Triple Negative Breast Cancer | 76 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07768436) |
| August 13, 2026 | NCT07762703 | Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS\<10), gBRCA Negative, Triple... | BreakBio Corp | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC) | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762703) |
| August 12, 2026 | NCT07760844 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC | Fudan University | Phase 3 | Not yet recruiting | Breast Cancer, Triple Negative Breast Cancer (TNBC) | 180 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760844) |
| August 7, 2026 | NCT07752550 | Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer | Harbin Medical University | Phase 2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC) | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752550) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| August 4, 2026 | NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | Iovance Biotherapeutics, Inc. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and... | 106 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743723) |
| August 4, 2026 | NCT07743632 | Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC | University of Kansas Medical Center | Phase 2 | Not yet recruiting | Breast Cancer, Triple Negative Breast Cancer | 110 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743632) |
| August 3, 2026 | NCT07743190 | A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative... | Medical University of South Carolina | Phase 2 | Recruiting | Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes | 55 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743190) |
| August 3, 2026 | NCT07741968 | A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer | City of Hope Medical Center | Not applicable | Recruiting | Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC... | 126 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741968) |
| July 31, 2026 | NCT07739485 | Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study | Liu Shu | Phase 1/2 | Recruiting | Triple -Negative Breast Cancer | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739485) |
| July 28, 2026 | NCT07730125 | Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies | CoRegen, Inc. | Phase 1/2 | Not yet recruiting | HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Prostate Cancer | 67 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730125) |
| July 28, 2026 | NCT07729956 | A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Triple-Negative Breast Cancer (TNBC) | 436 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729956) |
| July 23, 2026 | NCT07723469 | Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery | SURGE Therapeutics | Phase 3 | Not yet recruiting | TNBC - Triple-Negative Breast Cancer | 400 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723469) |
| July 23, 2026 | NCT07721259 | A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden | University of Washington | Phase 2 | Not yet recruiting | Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC... | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07721259) |
| July 20, 2026 | NCT07714382 | Survival Outcomes of Residual Disease in Triple-Negative Breast Cancer | Sohag University | Observational | Completed | Triple-Negative Breast Cancer (TNBC) | 100 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714382) |
| July 15, 2026 | NCT07705438 | Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC | Fudan University | Observational | Recruiting | Triple Negative Breast Cancer, Immune Checkpoint Inhibitor, Granzyme B PET/CT | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705438) |
| July 15, 2026 | NCT07705334 | A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors | SHY Therapeutics | Phase 1 | Recruiting | Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer, Gastric... | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705334) |
| July 13, 2026 | NCT07698106 | Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC | University Health Network, Toronto | Phase 1/2 | Recruiting | Triple-Negative Breast Cancer (TNBC) | 60 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698106) |
| July 7, 2026 | NCT07687446 | Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer | Assistance Publique - Hôpitaux de Paris | Observational | Not yet recruiting | Breast Cancer (Triple Negative Breast Cancer (TNBC)) | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07687446) |
| July 2, 2026 | NCT07681297 | Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and... | National University Hospital, Singapore | Phase 1/2 | Not yet recruiting | Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC), CNS Disease, Breast Cancer | 154 | Singapore | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07681297) |
| July 1, 2026 | NCT07679360 | A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Recruiting | Triple Negative Breast Cancer | 1,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679360) |
| June 29, 2026 | NCT07672431 | Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression | Barbara Ann Karmanos Cancer Institute | Not applicable | Not yet recruiting | Triple Negative Breast Cancer | 24 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07672431) |
| June 26, 2026 | NCT07671092 | Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC | RayzeBio, Inc. | Early phase 1 | Recruiting | Metastatic Urothelial Carcinoma, Breast Cancer, TNBC - Triple-Negative Breast Cancer, Hormone Receptor Positive HER-2... | 40 | Australia, New Zealand, South Africa | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671092) |
| June 25, 2026 | NCT07669610 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC | Fudan University | Phase 3 | Not yet recruiting | Breast Cancer, Triple Negative Breast Cancer (TNBC) | 140 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07669610) |
| June 23, 2026 | NCT07662252 | Circulating Tumor DNA Dynamics to Optimize Neoadjuvant Therapy in HER2-Positive and Triple-Negative Breast Cancer | Federico II University | Observational | Not yet recruiting | Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2 + Breast Cancer | 186 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662252) |
| June 17, 2026 | NCT07652242 | Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer | Immunomic Therapeutics, Inc. | Phase 1 | Recruiting | Triple Negative Breast Cancer (TNBC) | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652242) |
| June 12, 2026 | NCT07646106 | THE-0504 in Patients With Solid Tumors | Thena Biotech S.r.l. | Phase 1 | Recruiting | Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC), Gastric Cancer (GC), Triple -Negative Breast Cancer... | 30 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07646106) |
| June 10, 2026 | NCT07638852 | Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM. | Fudan University | Phase 2 | Recruiting | TNBC, Triple Negative Breast Cancer, Brain Metastasases | 58 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638852) |
| June 5, 2026 | NCT07630961 | Phase I Study of JFI447 \[68Ga\]Ga-DFC413 and Comparison to FFG233 \[68Ga\]Ga-NNS309 in Patients With Solid Tumors | Novartis Pharmaceuticals | Phase 1 | Recruiting | Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), HR+/HER2- Ductal Breast Cancer... | 66 | Denmark, Japan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630961) |
| June 3, 2026 | NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or... | GV20 Therapeutics | Phase 2 | Not yet recruiting | Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and... | 227 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623642) |
| June 3, 2026 | NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | Huahui Health | Phase 1 | Recruiting | Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell... | 299 | Australia, China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623369) |
| June 2, 2026 | NCT07619534 | Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior... | National Cancer Institute (NCI) | Observational | Recruiting | Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast | 139 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619534) |
| May 28, 2026 | NCT07610525 | Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Triple Negative Breast Cancer, Blood and Image Guided, Optimization of Neoadjuvant Therapy, Phase 2 | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610525) |
| May 22, 2026 | NCT07601178 | QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With... | Jiangsu Cancer Institute & Hospital | Phase 2 | Recruiting | TNBC, Triple Negative Breast Cancer | 34 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601178) |
| May 19, 2026 | NCT07597642 | ON-treatment Single-cell Analysis for the Identification of Early Tumor Response Biomarkers on Prospective Collected Serial Tumor Biopsies... | IRCCS San Raffaele | Not applicable | Not yet recruiting | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | 55 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07597642) |
| May 12, 2026 | NCT07581314 | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) | Telomir Pharmaceuticals, Inc. | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Advanced Triple-Negative Breast Cancer, Metastatic Triple-negative Breast Cancer | 76 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581314) |
| May 6, 2026 | NCT07570524 | Predicting Response to Immunochemotherapy in Early Triple Negative Breast Cancer | Center Eugene Marquis | Observational | Recruiting | Triple-negative Breast Cancer (TNBC) | 200 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570524) |
| April 29, 2026 | NCT07556848 | A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 3 | Not yet recruiting | Locally Advanced or Metastatic Triple-negative Breast Cancer | 356 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07556848) |
| April 29, 2026 | NCT07555210 | Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy | Jessica Mezzanotte Sharpe | Not applicable | Recruiting | Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer)... | 25 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555210) |
| April 27, 2026 | NCT07552181 | Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast... | Yuan Yuan | Phase 2 | Not yet recruiting | TNBC - Triple-Negative Breast Cancer, TNBC, Early Stage Triple-Negative Breast Carcinoma | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552181) |
| April 27, 2026 | NCT07551765 | Diet-drive Gut Microbiome and Outcome in Patients With Early-stage Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy and... | Barts & The London NHS Trust | Observational | Not yet recruiting | Triple Negative Breast Cancer (TNBC), Early Setting | 300 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551765) |
| April 24, 2026 | NCT07551050 | Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer | Fudan University | Observational | Recruiting | TNBC - Triple-Negative Breast Cancer | 300 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551050) |
| April 23, 2026 | NCT07546695 | Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple... | University Hospital, Basel, Switzerland | Observational | Recruiting | Breast Cancer | 600 | Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07546695) |
| April 22, 2026 | NCT07545122 | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative... | Context Therapeutics Inc. | Phase 1 | Recruiting | Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Urothelial Cancer | 162 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545122) |
| April 22, 2026 | NCT07544056 | A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer | BeBetter Med Inc | Phase 2/3 | Recruiting | Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer | 446 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07544056) |
| April 17, 2026 | NCT07536815 | An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced... | CytoDyn, Inc. | Not applicable | Temporarily not available | TNBC, TNBC - Triple-Negative Breast Cancer, TNBC, Triple Negative Breast Cancer | Not listed | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07536815) |
| April 16, 2026 | NCT07533123 | A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard... | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 3 | Recruiting | Triple Negative Breast Cancer | 364 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07533123) |
| April 14, 2026 | NCT07528768 | HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. | The University of The West Indies | Phase 2 | Not yet recruiting | Triple Negative Breast Cancer, Metastatic Triple-negative Breast Cancer | 750 | Barbados, Ghana, Jamaica | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07528768) |
| April 14, 2026 | NCT07527819 | Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC) | Peter MacCallum Cancer Centre, Australia | Observational | Not yet recruiting | Triple Negative Breast Cancer (TNBC) | 75 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527819) |
| April 13, 2026 | NCT07525869 | An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC... | Yonsei University | Not applicable | Recruiting | Triple-Negative Breast Cancer | 40 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07525869) |
| April 13, 2026 | NCT07523789 | Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC | The First Affiliated Hospital with Nanjing Medical University | Observational | Not yet recruiting | TNBC, Triple Negative Breast Cancer | 201 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523789) |
| April 13, 2026 | NCT07523529 | Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors | Beijing Biotech | Phase 1/2 | Recruiting | Advanced Unresectable, Metastatic | 72 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523529) |
| April 8, 2026 | NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 | Recruiting | Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin... | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517198) |
| April 7, 2026 | NCT07513311 | A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer | Massachusetts General Hospital | Not applicable | Recruiting | Triple Negative Breast Cancer (TNBC) | 75 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07513311) |
| April 6, 2026 | NCT07510802 | Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC | Beijing Biotech | Phase 1/2 | Recruiting | Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510802) |
| April 3, 2026 | NCT07509515 | QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. | Fudan University | Phase 2 | Not yet recruiting | Triple-negative Breast Cancer (TNBC) | 60 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509515) |
| March 31, 2026 | NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | IDEAYA Biosciences | Phase 1 | Recruiting | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal... | 150 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503808) |
| March 27, 2026 | NCT07498400 | Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer | Xijing Hospital | Not applicable | Active not recruiting | Breast Cancer (Triple Negative Breast Cancer (TNBC)), Breast Cancer | 216 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07498400) |
| March 23, 2026 | NCT07487519 | Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or... | Shanghai Henlius Biotech | Phase 2 | Not yet recruiting | Breast Cancer (Triple Negative Breast Cancer (TNBC)) | 180 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07487519) |
| March 20, 2026 | NCT07486687 | Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab... | The Netherlands Cancer Institute | Phase 3 | Not yet recruiting | Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative... | 1,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07486687) |
| March 20, 2026 | NCT07486089 | Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) | Beijing Biotech | Phase 1/2 | Recruiting | Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC) | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07486089) |
| March 20, 2026 | NCT07484776 | Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer | Universidad Europea de Madrid | Not applicable | Active not recruiting | Triple-Negative Breast Cancer (TNBC) | 40 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07484776) |
| March 17, 2026 | NCT07478705 | Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging | Sunnybrook Health Sciences Centre | Not applicable | Not yet recruiting | Triple Negative Breast Cancer, Surveillance, Recurrence, ctDNA | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07478705) |
| March 13, 2026 | NCT07471815 | Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy | Harbin Medical University | Phase 2 | Active not recruiting | Breast Cancer Triple Negative Breast Cancer | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07471815) |
| March 12, 2026 | NCT07466303 | Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer | Xijing Hospital | Phase 2 | Not yet recruiting | Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer | 84 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07466303) |
| March 9, 2026 | NCT07458204 | Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer | Institut Jean-Godinot | Phase 2 | Not yet recruiting | Triple-negative Breast Cancer | 760 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07458204) |
| March 9, 2026 | NCT07458113 | Sac-TMT for Active TNBC Brain Metastases | Yale University | Phase 2 | Not yet recruiting | Metastatic Triple Negative Breast Cancers | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07458113) |
| March 9, 2026 | NCT07457359 | Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Recruiting | TNBC, Triple Negative Breast Cancer | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07457359) |
| March 2, 2026 | NCT07441512 | A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced... | Hu Hai | Phase 2 | Not yet recruiting | TNBC - Triple-Negative Breast Cancer, TNBC | 26 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441512) |
| February 20, 2026 | NCT07423117 | A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy | IntoCell, Inc | Phase 1 | Enrolling by invitation | Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Metastatic... | 102 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07423117) |
| February 19, 2026 | NCT07421479 | Patient-Derived Breast Cancer Organoids for Therapeutic Extracellular Vesicle Isolation (PDO-Mercurial01) | Istituti Clinici Scientifici Maugeri SpA | Observational | Active not recruiting | Invasive Breast Cancer | 50 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421479) |
| February 19, 2026 | NCT07419880 | Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer | Fudan University | Phase 2 | Not yet recruiting | Triple -Negative Breast Cancer | 46 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07419880) |
| February 17, 2026 | NCT07413601 | Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in... | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Not yet recruiting | Triple Negative Breast Cancer Metastatic | 78 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07413601) |
| February 12, 2026 | NCT07407517 | Adjuvant Intensification for LAR | Fudan University | Phase 3 | Not yet recruiting | Breast Cancer Females, Triple Negative Breast Cancer (TNBC) | 904 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407517) |
| February 10, 2026 | NCT07401537 | Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast... | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Recruiting | Triple -Negative Breast Cancer, Breast Cancer | 416 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07401537) |
| February 6, 2026 | NCT07394387 | Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer. | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Triple Negative Breast Cancer (TNBC) | 58 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07394387) |
| January 30, 2026 | NCT07378306 | FMD and Neoadjuvant Chemo-immunotherapy in TNBC | Sun Yat-sen University | Phase 2 | Recruiting | Breast Cancer | 80 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07378306) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Fudan University | 17 | October 20, 2026 |
| Tianjin Medical University Cancer Institute and Hospital | 6 | January 6, 2026 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 5 | February 10, 2026 |
| Harbin Medical University | 4 | August 7, 2026 |
| Xijing Hospital | 4 | March 27, 2026 |
| Merck Sharp & Dohme LLC | 4 | May 13, 2025 |
| Istituti Clinici Scientifici Maugeri SpA | 3 | September 8, 2026 |
| Novartis Pharmaceuticals | 3 | September 3, 2026 |
| City of Hope Medical Center | 3 | August 3, 2026 |
| National Cancer Institute (NCI) | 3 | June 2, 2026 |
| Beijing Biotech | 3 | April 13, 2026 |
| Yale University | 3 | March 9, 2026 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 3 | February 17, 2026 |
| Sun Yat-sen University | 3 | January 30, 2026 |
| UNC Lineberger Comprehensive Cancer Center | 3 | January 14, 2026 |
| Henan Cancer Hospital | 3 | December 2, 2025 |
| Peking University Cancer Hospital & Institute | 3 | July 1, 2025 |
| Washington University School of Medicine | 2 | November 3, 2026 |
| Shanghai Junshi Bioscience Co., Ltd. | 2 | October 15, 2026 |
| Assistance Publique - Hôpitaux de Paris | 2 | September 22, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 87 | November 3, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 38 | October 19, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 33 | October 26, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 27 | October 27, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 27 | October 21, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 18 | October 19, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 3 | April 22, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 2 | June 26, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 1 | April 10, 2025 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 77 | November 3, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 74 | October 19, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 16 | October 21, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 13 | September 3, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 11 | September 8, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 11 | July 13, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 10 | April 13, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 8 | September 3, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 8 | March 20, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 6 | April 27, 2026 |
| [Israel](https://specstream.ai/data/clinical-trials/country/israel) | 6 | January 8, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 6 | December 3, 2025 |
| [Colombia](https://specstream.ai/data/clinical-trials/country/colombia) | 4 | October 2, 2026 |
| [Greece](https://specstream.ai/data/clinical-trials/country/greece) | 4 | September 15, 2026 |
| [Singapore](https://specstream.ai/data/clinical-trials/country/singapore) | 4 | July 2, 2026 |
| [Portugal](https://specstream.ai/data/clinical-trials/country/portugal) | 4 | May 13, 2025 |
| [New Zealand](https://specstream.ai/data/clinical-trials/country/new-zealand) | 3 | June 26, 2026 |
| [South Africa](https://specstream.ai/data/clinical-trials/country/south-africa) | 3 | June 26, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 3 | June 5, 2026 |
| [Argentina](https://specstream.ai/data/clinical-trials/country/argentina) | 3 | May 13, 2025 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 3 | May 13, 2025 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 3 | May 13, 2025 |
| [Chile](https://specstream.ai/data/clinical-trials/country/chile) | 3 | May 13, 2025 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 3 | May 13, 2025 |
| [Romania](https://specstream.ai/data/clinical-trials/country/romania) | 3 | May 13, 2025 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).